The PE Ratio as of November 2024 (TTM) for bluebird bio, Inc. (BLUE) is -0.19

According to bluebird bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.19. This represents a change of -67.16% compared to the average of -0.58 of the last 4 quarters.

bluebird bio, Inc. (BLUE) Historical PE Ratio (quarterly & annually)

How has BLUE PE Ratio performed in the past?

The mean historical PE Ratio of bluebird bio, Inc. over the last ten years is -7.84. The current -0.19 PE Ratio has changed 142.29% with respect to the historical average. Over the past ten years (40 quarters), BLUE's PE Ratio was at its highest in in the December 2022 quarter at 4.57. The PE Ratio was at its lowest in in the June 2020 quarter at -27.80.

bluebird bio, Inc. (BLUE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of bluebird bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

bluebird bio, Inc. (BLUE) Average PE Ratio

How has BLUE PE Ratio performed in the past?

The current PE Ratio of bluebird bio, Inc. (BLUE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

bluebird bio, Inc. (BLUE) PE Ratio vs. Peers

How is BLUE’s PE Ratio compared to its peers?

bluebird bio, Inc.’s PE Ratio is greater than Mersana Therapeutics, Inc. (-3.36), greater than Zentalis Pharmaceuticals, Inc. (-1.28), greater than Y-mAbs Therapeutics, Inc. (-19.47), greater than Travere Therapeutics, Inc. (-4.04), greater than Madrigal Pharmaceuticals, Inc. (-14.57), greater than Viking Therapeutics, Inc. (-58.83), less than Sarepta Therapeutics, Inc. (89.43), greater than Hepion Pharmaceuticals, Inc. (-0.20), greater than PTC Therapeutics, Inc. (-7.34), less than Agios Pharmaceuticals, Inc. (4.70), greater than Intercept Pharmaceuticals, Inc. (-91.78), greater than Karyopharm Therapeutics Inc. (-1.21), less than CureVac N.V. (0), less than Reata Pharmaceuticals, Inc. (5.18), greater than Krystal Biotech, Inc. (-20.07), less than Vir Biotechnology, Inc. (104.40), greater than Propanc Biopharma, Inc. (-1.82), less than null (-0.09),

Build a custom stock screener for bluebird bio, Inc. (BLUE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like bluebird bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

bluebird bio, Inc. (BLUE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like bluebird bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.